Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations for RSV dropped by 78% following nirsevimab rollout in Madrid maternity wards.